WO1996023489A3 - Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen - Google Patents

Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen Download PDF

Info

Publication number
WO1996023489A3
WO1996023489A3 PCT/EP1996/000381 EP9600381W WO9623489A3 WO 1996023489 A3 WO1996023489 A3 WO 1996023489A3 EP 9600381 W EP9600381 W EP 9600381W WO 9623489 A3 WO9623489 A3 WO 9623489A3
Authority
WO
WIPO (PCT)
Prior art keywords
carotinoids
preparing medicaments
treating dermatoses
treating
dermatoses
Prior art date
Application number
PCT/EP1996/000381
Other languages
English (en)
French (fr)
Other versions
WO1996023489A2 (de
Inventor
Wolfgang Schmutzler
Karl Kolter
Original Assignee
Basf Ag
Wolfgang Schmutzler
Karl Kolter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1995103604 external-priority patent/DE19503604A1/de
Priority claimed from DE1995139743 external-priority patent/DE19539743A1/de
Application filed by Basf Ag, Wolfgang Schmutzler, Karl Kolter filed Critical Basf Ag
Priority to EP96902950A priority Critical patent/EP0806946A2/de
Priority to JP8523252A priority patent/JPH10513444A/ja
Priority to US08/875,622 priority patent/US5886053A/en
Priority to AU47157/96A priority patent/AU4715796A/en
Publication of WO1996023489A2 publication Critical patent/WO1996023489A2/de
Publication of WO1996023489A3 publication Critical patent/WO1996023489A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Verwendung von Carotinoiden zur Herstellung von Arzneimitteln zur Behandlung von entzündlichen Erkrankungen, die nicht durch Lichteinwirkung oder eine Infektion mit Mikroorganismen hervorgerufen werden.
PCT/EP1996/000381 1995-02-03 1996-02-02 Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen WO1996023489A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP96902950A EP0806946A2 (de) 1995-02-03 1996-02-02 Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen
JP8523252A JPH10513444A (ja) 1995-02-03 1996-02-02 皮膚疾患の治療のための医薬品の製造のためのカロチノイドの使用
US08/875,622 US5886053A (en) 1995-02-03 1996-02-02 Use of carotenoids for producing drugs for the treatment of dermatoses
AU47157/96A AU4715796A (en) 1995-02-03 1996-02-02 Use of carotinoids for preparing medicaments for treating dermatoses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE1995103604 DE19503604A1 (de) 1995-02-03 1995-02-03 Verwendung von Carotinoiden zur Herstellung von Arzneimitteln zur Behandlung von Dermatosen
DE19503604.2 1995-02-03
DE19539743.6 1995-10-25
DE1995139743 DE19539743A1 (de) 1995-10-25 1995-10-25 Verwendung von Carotinoiden zur Herstellung von Arzneimitteln zur Behandlung von entzündlichen Erkrankungen

Publications (2)

Publication Number Publication Date
WO1996023489A2 WO1996023489A2 (de) 1996-08-08
WO1996023489A3 true WO1996023489A3 (de) 1996-10-03

Family

ID=26012140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/000381 WO1996023489A2 (de) 1995-02-03 1996-02-02 Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen

Country Status (6)

Country Link
US (1) US5886053A (de)
EP (1) EP0806946A2 (de)
JP (1) JPH10513444A (de)
AU (1) AU4715796A (de)
CA (1) CA2210957A1 (de)
WO (1) WO1996023489A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19653410A1 (de) * 1996-12-20 1998-06-25 Basf Ag Verwendung von Carotinoid-Solubilisaten zum Färben von Lebensmitteln und pharmazeutischen Zubereitungen
SE522246C2 (sv) 1997-02-27 2004-01-27 Astacarotene Ab Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion
AU752468B2 (en) 1997-04-04 2002-09-19 Phyllis E. Bowen Lutein esters having high bioavailability
SE512531C2 (sv) 1997-09-04 2000-03-27 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
SE511237C2 (sv) * 1997-12-16 1999-08-30 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor
SE524337C2 (sv) * 1998-10-16 2004-07-27 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk behandling av matsmältningsbesvär
SE9903619D0 (sv) * 1999-10-07 1999-10-07 Astacarotene Ab Use and method of treatment
SE0001071D0 (sv) * 2000-03-27 2000-03-27 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines
US7078040B2 (en) * 2000-03-27 2006-07-18 Fuji Chemical Industry Co., Ltd. Method of inhibiting the expression of inflammatory cytokines and chemokines
DE10221212A1 (de) * 2002-05-13 2003-11-27 Andreas Maack Sporopollenin enthaltende lösliche Zusammensetzung und Verwendung
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
AU2003256982A1 (en) 2002-07-29 2004-02-16 Cardax Pharmaceuticals, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
JP3780236B2 (ja) * 2002-08-07 2006-05-31 キヤノン株式会社 ガスが浸透した材料の保管方法
US7097905B2 (en) * 2002-10-18 2006-08-29 Kolon Industries, Inc. Microcellular foamed fiber, and a process of preparing for the same
EP1750723A1 (de) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid-analoga oder derivate zur hemmung und linderung von entzündungen
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US7351424B2 (en) * 2004-07-22 2008-04-01 Bio Lut S.A. De C.V. Enhanced purity trans-lutein-ester compositions and methods of making same
US20060269497A1 (en) * 2005-05-27 2006-11-30 Yamaha Hatsudoki Kabushiki Kaisha Trichogenous agent
FR2935610B1 (fr) * 2008-09-05 2010-10-29 Lvmh Rech Composition cosmetique ou dermatologique contenant un melange d'huiles essentielles et son utilisation, notamment pour le soin des peaux sensibles ou sensibilisees
TWI492744B (zh) * 2009-12-04 2015-07-21 Abbott Lab 使用類胡蘿蔔素調節早產兒發炎症之方法
US9034342B2 (en) * 2010-03-25 2015-05-19 Gateway Health Alliances, Inc Methods and compositions to reduce fat gain, promote weight loss in animals

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542632A1 (de) * 1991-11-14 1993-05-19 LABORATOIRES ARKOPHARMA Société Anonyme Verwendung von Beta-Karotin zur Behandlung von Asthma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
DE4031094A1 (de) * 1990-10-02 1992-04-09 Basf Ag Verfahren zur herstellung von stabilen injizierbaren (beta)-carotin-solubilisaten

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542632A1 (de) * 1991-11-14 1993-05-19 LABORATOIRES ARKOPHARMA Société Anonyme Verwendung von Beta-Karotin zur Behandlung von Asthma

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ABAD-LACRUZ A ET AL: "PLASMA VITAMINS A AND E IN HOSPITALIZED PATIENTS WITH INFLAMMATORY BOWEL DISEASE IBD", 9TH CONGRESS OF THE EUROPEAN SOCIETY OF PARENTERAL AND ENTERAL NUTRITION, BARCELONA, SPAIN, SEPTEMBER 13-16, 1987. CLIN NUTR (EDINB), 6 (SPEC. SUPPL.). 1987. 36., XP000577901 *
BOLSMANN K ET AL: "Histamine release from mast cells and monocytes: The effects of azelastine, reproterol and vitamin A-analogues", INFLAMMATION RESEARCH, 45 (SUPPL. 1). 1996. S5-S6., XP000577938 *
FLORENCE TM: "The role of free radicals in disease.", AUST N Z J OPHTHALMOL, FEB 1995, 23 (1) P3-7, AUSTRALIA, XP000577875 *
FRANCESCHINI PH. ET AL: "Treatment of lupus erythematosus and photosensitive dermatoses with carotenoids", NOUV. PRESSE MED., 1981, 10/23 (1938), FRANCE, XP000578401 *
GONZALEZ-HUIX F ET AL: "VITAMIN STATUS IN PATIENTS WITH CROHN'S DISEASE CD", 9TH CONGRESS OF THE EUROPEAN SOCIETY OF PARENTERAL AND ENTERAL NUTRITION, BARCELONA, SPAIN, SEPTEMBER 13-16, 1987. CLIN NUTR (EDINB), 6 (SPEC. SUPPL.). 1987. 70., XP000577902 *
LAWLOR F. ET AL: "Exploration of new therapeutic strategies in urticaria as a result of clinically orientated research", Z. HAUTKR., 1990, 65/1 (17-27), GERMANY, FEDERAL REPUBLIC OF, XP000577984 *
OBERLIN P. ET AL: "Amicrobial pustulosis and systemic lupus erythematosus", ANN. DERMATOL. VENEREOL., 1991, 118/11 (824-825), FRANCE, XP000578412 *
SCHEURLEN C ET AL: "Endogenous antioxidant status in inactive Crohn's disease complicated by intestinal strictures and fistulae", GASTROENTEROLOGY, 106 (4 SUPPL.). 1994. A768., XP000577983 *

Also Published As

Publication number Publication date
EP0806946A2 (de) 1997-11-19
AU4715796A (en) 1996-08-21
JPH10513444A (ja) 1998-12-22
CA2210957A1 (en) 1996-08-08
US5886053A (en) 1999-03-23
WO1996023489A2 (de) 1996-08-08

Similar Documents

Publication Publication Date Title
WO1996023489A3 (de) Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen
AU3202595A (en) 1,2-substituted imidazolyl compounds for the treatment of inflammation
TR199901905T2 (xx) 2-(P�rin-9-il)-tetrahidrofuran-3,4-diol t�revleri.
AU4613999A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
TR199800585T2 (xx) COX-2 �nhibit�rleri Olarak (Metils�lfonil)Fenil-2-(5H)-Furanonlar.
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
NO971816L (no) Farmasöytisk blanding for behandling av sykdommer forårsaket av IL-6 produksjon
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
MX9702658A (es) Derivados novedosos de acido carboxilico, su preparacion y uso.
NO965516D0 (no) Sterolderivater anvendt til regulering av meiose
ATE25246T1 (de) Triphenylimidazolyloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
FI98067B (fi) Uusia alkyleenidiammoniumdiklavulanaattijohdannaisia, menetelmä niidenvalmistamiseksi samoin kuin niiden käyttö kalvulaanihapon puhdistamiseksi
DK0859615T3 (da) Carbostyrilderivat til helbredelse af ophthalmologiske sygdomme
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
AU6858996A (en) Pharmaceutical compositions for the treatment of infectious diseases
IS4367A (is) CCK eða gastrín temprandi 5-heterósýklísk-1,5-bensódíazepín
BR9612074A (pt) Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas
AU1192397A (en) Substituted thiazolines and their use for controlling animal pests
CA2267165A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
AU639746B2 (en) Use of benzylphosphonic acid derivatives for the treatment of diseases caused by viruses
AU6722498A (en) Disubstituted biphenyloxazolines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996902950

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08875622

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2210957

Country of ref document: CA

Ref country code: CA

Ref document number: 2210957

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 523252

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996902950

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996902950

Country of ref document: EP